Using selected fragments of peanut proteins, Australian biotechnology company Aravax has developed a product that switches off allergic reactions. The product is designed to be safer, more rapid and more convenient than other approaches currently under development.
The company has just commenced clinical trials of the potentially life-changing product and anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.

Read more